Trial reportThe American journal of psychiatry2024
Effects of Bundling Medication for Opioid Use Disorder With an mHealth Intervention Targeting Addiction: A Randomized Clinical Trial.
Trial report in The American journal of psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of Dropout and Influencing Factors in Digital Psychosocial Intervention Trials for Adult Illicit Substance Users: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2025Pooled it
- Development of the Healthy Women Intervention to Increase Women's Engagement in Medication Treatment for Opioid Use Disorder: Mixed Methods, User-Centered Design Approach.JMIR formative research · 2026Article
- Designing mHealth Apps for Substance Use Recovery Through Real-World Co-Design and Deployment: Mixed Methods Study.JMIR mHealth and uHealth · 2026Article
- A Mobile Health Application to Support Reductions in Overdose Risk Behaviors: A Pilot Study.Substance use & addiction journal · 2026Article
- Personalizing ecological momentary intervention for substance use disorders through data-driven decision rules.Frontiers in psychiatry · 2026Review
- Review
- Implementing real-time assessments of substance use cravings, triggers, and mood: a feasibility study with justice-involved populations.Health & justice · 2025Article
- The Development of a Patient-Centered Digital Health Care Technology for Young Adults in Opioid Use Disorder Treatment: Qualitative Study.JMIR formative research · 2025Article
- Clinical Management of Medication-Assisted Treatment for Opioid Use Disorder Using a Mobile Health App Within a Primary Care Clinic: Quasi-Experimental Study.JMIR formative research · 2025Article
- Digital Psychosocial Interventions Tailored for People in Opioid Use Disorder Treatment: Scoping Review.Journal of medical Internet research · 2025Article
- Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder.Expert opinion on pharmacotherapy · 2025Review
- Mobile Health Tool to Capture Social Determinants of Health and Their Impact on HIV Treatment Outcomes Among People Who Use Drugs: Pilot Feasibility Study.JMIR formative research · 2025Article
- Development and Evaluation of a Digital App for Patient Self-Management of Opioid Use Disorder: Usability, Acceptability, and Utility Study.JMIR formative research · 2024Article
- Community Supervision Engagement to Examine Health Outcomes: A Scoping Review.Public health nursing (Boston, Mass.)Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
objectiveMedication for opioid use disorder (MOUD) improves treatment retention and reduces illicit opioid use. A-CHESS is an evidence-based smartphone intervention shown to improve addiction-related behaviors. The authors tested the efficacy of MOUD alone versus MOUD plus A-CHESS to determine whether the combination further improved outcomes.
methodsIn an unblinded parallel-group randomized controlled trial, 414 participants recruited from outpatient programs were assigned in a 1:1 ratio to receive either MOUD alone or MOUD+A-CHESS for 16 months and were followed for an additional 8 months. All participants were on methadone, buprenorphine, or injectable naltrexone. The primary outcome was abstinence from illicit opioid use; secondary outcomes were treatment retention, health services use, other substance use, and quality of life; moderators were MOUD type, gender, withdrawal symptom severity, pain severity, and loneliness. Data sources were surveys comprising multiple validated scales, as well as urine screens, every 4 months.
resultsThere was no difference in abstinence between participants in the MOUD+A-CHESS and MOUD-alone arms across time (odds ratio=1.10, 95% CI=0.90-1.33). However, abstinence was moderated by withdrawal symptom severity (odds ratio=0.95, 95% CI=0.91-1.00) and MOUD type (odds ratio=0.57, 95% CI=0.34-0.97). Among participants without withdrawal symptoms, abstinence rates were higher over time for those in the MOUD+A-CHESS arm than for those in the MOUD-alone arm (odds ratio=1.30, 95% CI=1.01-1.67). Among participants taking methadone, those in the MOUD+A-CHESS arm were more likely to be abstinent over time (b=0.28, SE=0.09) than those in the MOUD-alone arm (b=0.06, SE=0.08), although the two groups did not differ significantly from each other (∆b=0.22, SE=0.11). MOUD+A-CHESS was also associated with greater meeting attendance (odds ratio=1.25, 95% CI=1.05-1.49) and decreased emergency department and urgent care use (odds ratio=0.88, 95% CI=0.78-0.99).
conclusionsOverall, MOUD+A-CHESS did not improve abstinence relative to MOUD alone. However, MOUD+A-CHESS may provide benefits for subsets of patients and may impact treatment utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.